Literature DB >> 7546255

Pain in burn patients.

J Latarjet1, M Choinère.   

Abstract

While severe pain is a constant component of the burn injury, inadequate pain management has been shown to be detrimental to burn patients. Pain-generating mechanisms in burns include nociception, primary and secondary hyperalgesia and neuropathy. The clinical studies of burn pain characteristics reveal very clear-cut differences between continuous pain and pain due to therapeutic procedures which have to be treated separately. Some of the main features of burn pain are: (1) its long-lasting course, often exceeding healing time, (2) the repetition of highly nociceptive procedures which can lead to severe psychological disturbances if pain control is inappropriate. Pharmaco-therapy with opioids is the mainstay for analgesia in burned patients, but non-pharmacological techniques may be useful adjuncts. Routine pain evaluation is mandatory for efficient and safe analgesia. Special attention must be given to pain in burned children which remains too often underestimated and undertreated. More educational efforts from physicians and nursing staff are necessary to improve pain management in burned patients.

Entities:  

Mesh:

Year:  1995        PMID: 7546255     DOI: 10.1016/0305-4179(95)00003-8

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  20 in total

1.  Puerarin alleviates burn-related procedural pain mediated by P2X(3) receptors.

Authors:  Xin Li; Jun Zhang; Yun Gao; Yang Yang; Changshui Xu; Guilin Li; Guanghua Guo; Shuangmei Liu; Jinyan Xie; Shangdong Liang
Journal:  Purinergic Signal       Date:  2011-07-22       Impact factor: 3.765

2.  Assessing the feasibility of implementing low-cost virtual reality therapy during routine burn care.

Authors:  Cameron G Ford; Ellen M Manegold; Cameron L Randall; Ariel M Aballay; Christina L Duncan
Journal:  Burns       Date:  2018-01-02       Impact factor: 2.744

3.  On-Demand Dissolution of a Dendritic Hydrogel-based Dressing for Second-Degree Burn Wounds through Thiol-Thioester Exchange Reaction.

Authors:  Marlena D Konieczynska; Juan C Villa-Camacho; Cynthia Ghobril; Miguel Perez-Viloria; Kristie M Tevis; William A Blessing; Ara Nazarian; Edward K Rodriguez; Mark W Grinstaff
Journal:  Angew Chem Int Ed Engl       Date:  2016-07-13       Impact factor: 15.336

4.  Pain response and pain control in burn patients.

Authors:  O Castana; G Anagiotos; G Rempelos; A Adalopoulou; C Kokkinakis; M Giannakidou; D B Diplas; D Alexakis
Journal:  Ann Burns Fire Disasters       Date:  2009-06-30

5.  Burn Survivors' Experience of Core Outcomes during Return to Life: a Qualitative Study.

Authors:  Vahid Zamanzadeh; Leila Valizadeh; Mojgan Lotfi; Feridoon Salehi
Journal:  J Caring Sci       Date:  2014-12-01

6.  Opiates and the development of post-injury complications: a review.

Authors:  Martin G Schwacha
Journal:  Int J Clin Exp Med       Date:  2008-01-20

7.  EMLA anaesthetic cream for debridement of burns: a study of plasma concentrations of lidocaine and prilocaine and a review of the literature.

Authors:  Stefan Lillieborg; Leif Aanderud
Journal:  Int J Burns Trauma       Date:  2017-10-25

Review 8.  Analgo-sedation of patients with burns outside the operating room.

Authors:  Cesare Gregoretti; Daniela Decaroli; Quirino Piacevoli; Alice Mistretta; Nicoletta Barzaghi; Nicola Luxardo; Irene Tosetti; Luisa Tedeschi; Laura Burbi; Paolo Navalesi; Fabio Azzeri
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Clinical and histological correlation in post-burn hypertrophic scar for pain and itching sensation.

Authors:  Young-Hee Choi; Kwang-Min Kim; Hye-One Kim; Young-Chul Jang; In-Suk Kwak
Journal:  Ann Dermatol       Date:  2013-11-30       Impact factor: 1.444

Review 10.  Bench-to-bedside review: Burn-induced cerebral inflammation--a neglected entity?

Authors:  Michael A Flierl; Philip F Stahel; Basel M Touban; Kathryn M Beauchamp; Steven J Morgan; Wade R Smith; Kyros R Ipaktchi
Journal:  Crit Care       Date:  2009-06-29       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.